The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
Open accessAbstract
Recent studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple subclones. It is not known whether specific gene mutations typically occur in founding clones or subclones. We screened a panel of 94 candidate genes in a cohort of 157 patients with MDS or secondary acute myeloid leukemia (sAML). This included 150 cases with samples obtained at MDS diagnosis and 15 cases with samples obtained at sAML transformation (8 were also analyzed at the MDS stage). We performed whole-genome sequencing (WGS) to define the clonal architecture in eight sAML genomes and identified the range of variant allele frequencies (VAFs) for founding clone mutations. At least one mutation or cytogenetic abnormality was detected in 83% of the 150 MDS patients and 17 genes were significantly mutated (false discovery rate ≤0.05). Individual genes and patient samples displayed a wide range of VAFs for recurrently mutated genes, indicating that no single gene is exclusively mutated in the founding clone. The VAFs of recurrently mutated genes did not fully recapitulate the clonal architecture defined by WGS, suggesting that comprehensive sequencing may be required to accurately assess the clonal status of recurrently mutated genes in MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,954
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citationFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citationClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Self-citationDNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationSomatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
The structure of the G protein heterotrimer Giα1β1γ2
Wall, M. A., Coleman, D. E., Lee, E. N., Iñiguez-Lluhı́, J. A., Posner, B. A., Gilman, A. G., & Sprang, S. R. (1995) · Cell · doi:10.1016/0092-8674(95)90220-1 · Cited by 1,140
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–284 of 284
Moiseev, I., Tcvetkov, N., Epifanovskaya, O., Babenko, E. V., Parfenenkova, A., Bakin, E., Yurovskaya, K., & Morozova, Е. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275399 · Cited by 8
“Myelodysplastic syndrome (MDS) is a heterogenic group of diseases characterized by accumulation of somatic mutations in hematopoietic stem cells [1–3] and bone marrow niche abnormalities [4] which lead to ineffective hematopoiesis, cytopenia and possible transformation into acute myeloid leukemia…”
Zhang, X., Lancet, J. E., & Zhang, L. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1037756 · Cited by 8
Najima, Y., Tachibana, T., Takeda, Y., Koda, Y., Aoyama, Y., Toya, T., Igarashi, A., Tanaka, M., Sakaida, E., Abe, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04981-x · Cited by 8
“Genomic and epigenetic differences between MDS and AML have been revealed with the development of molecular and genetic research techniques [25, 26].”
BackgroundThe genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications
Malcovati, L., Ambaglio, I., & Elena, C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000229 · Cited by 8
Wang, J., Ai, X., Qin, T., Xu, Z., Zhang, Y., Liu, J., Li, B., Fang, L., Zhang, H., Pan, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13688 · Cited by 8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders
Lasho, T. L., & Patnaik, M. M. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00719-2 · Cited by 8
“Other genes involved in growth/transcription, splicing machinery, and DNA damage repair: TP53 , JAK2 , SF3B1 , CBL , SRSF2 , PPM1D , and BCOR are also differentially mutated but are less frequent [97, 98].”
Suh, K. J., Cheong, J., Kim, I., Kim, H., Shin, D., Koh, Y., Yoon, S. S., Min, Y. H., Ahn, J., Kim, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166245 · Cited by 7
Bernardi, S., Farina, M., Zanaglio, C., Cattina, F., Polverelli, N., Schieppati, F., Re, F., Foroni, C., Malagola, M., Dunbar, A. J., et al. (2020) · Case Reports in Hematology · doi:10.1155/2020/2795656 · Cited by 7
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories
Guarnera, L., Fabiani, E., Silvestrini, G., Attardi, E., & Voso, M. T. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.06.005 · Cited by 9
Duncavage, E. J., OʼBrien, J., Vij, K. R., Miller, C. A., Chang, G. S., Shao, J., Jacoby, M. A., Heath, S. C., Janke, M. R., Elliott, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.247 · Cited by 6
“Genomic DNA was extracted from bone marrow and skin (as a source of normal DNA) and enriched for the coding exons of a panel of 284 commonly mutated myeloid genes (Supplementary Table 1).(5-8) DNA was extracted from aspirate coverslips for follow-up cases when cryopreserved cells were not available.”
BackgroundMethodSelf-citationMolecular Testing in Patients with Suspected Myelodysplastic Syndromes
Moyo, T. K., & Savona, M. R. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0356-8 · Cited by 7
Huang, H., Qin, T., Xu, Z., Shi, Z., Li, B., Pan, L., Hu, N., Qu, S., Huang, G., Gale, R. P., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16326 · Cited by 6
Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms
Patel, B. J., Hirsch, C. M., Clemente, M. J., Sekeres, M. A., Makishima, H., & Maciejewski, J. P. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1747-7 · Cited by 6
“One of the major conclusions of NGS studies was recognition of intratumor heterogeneity and complex hierarchical clonal structure in leukemia [22, 23] including MDS (Fig.”
BackgroundParidar, M., Ghalesardi, O. K., Seghatoleslami, M., Ahmadzadeh, A., Khosravi, A., & Saki, N. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2016.61 · Cited by 6
The Etiology of Acute Leukemia
Nichol, J. N., Assouline, S. E., & Miller, W. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_14 · Cited by 6
Walter, M. J. (2015) · Blood · doi:10.1182/blood-2015-01-621193 · Cited by 6
Self-citationDo somatic mutations in de novo MDS predict for response to treatment?
Schroeder, M. A., & Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.317 · Cited by 6
Lichtman, M. A. (2013) · Leukemia · doi:10.1038/leu.2013.209 · Cited by 6
Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes
Kwon, A. J., & Weinberg, O. K. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.07.001 · Cited by 7
Zhang, L., Deeb, G., Deeb, K. K., Vale, C., Barclift, D. P., & Papadantonakis, N. (2024) · Cancers · doi:10.3390/cancers16081503 · Cited by 8
“A high percentage of patients with MDS carry more than one MDS-associated mutation, and there is significant clonal diversity [33–36] in the neoplastic population of MDS.”
Backgroundde Pedro, M. S., Wang, W., Kanagal‐Shamanna, R., & Khoury, J. D. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0483-5 · Cited by 5
Wang, J. Y., Ma, J., Lin, Y. N., Wang, J., Shen, H., Gui, F. M., Han, C., Li, Q. H., Song, Z., & Wang, X. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.03.004 · Cited by 5
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAs
Garcia, G. R., Palangat, M., Moraly, J., Donovan, B. T., Wang, B., Phadke, I., Sturgill, D. M., Chen, J., Zhang, G., Holewinski, R. J., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.03.006 · Cited by 5
Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome
Pečánková, K., Májek, P., Čermák, J., & Dyr, J. E. (2015) · BioMed Research International · doi:10.1155/2015/872983 · Cited by 4
Hebeda, K. M., Boudová, L., Beham‐Schmid, C., Orazi, A., Kvasnicka, H. M., Gianelli, U., & Tzankov, A. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04307-9 · Cited by 4
“On the contrary, other mutations (type-2 TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2, and TET2) were enriched in high-risk MDS but had a weaker impact on MDS progression and overall survival.”
BackgroundPatel, B. J., Barot, S. V., Xie, Y., Cook, J. R., Carraway, H. E., & Hsi, E. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1876860 · Cited by 4
The Etiology of Acute Leukemia
Nichol, J. N., Kinal, M., & Miller, W. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_12 · Cited by 4
Clonotyping for precision oncology
Dang, H. X., & Maher, C. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.010 · Cited by 3
Ferrone, C. K., McNaughton, A. J. M., Rashedi, I., Ring, B. A., Buckstein, R. J., Tsui, H., & Rauh, M. J. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100068 · Cited by 3
Liu, Y., Cheng, H.-C., Cheng, M., Sun, M., Ma, J., & Gong, T. (2024) · Hematology · doi:10.1080/16078454.2024.2392469 · Cited by 3
A germline ETV6 mutation disrupts hematopoiesis via de novo creation of a nuclear export signal
McConville, M., Thomas, T., Beckner, R. L., Kroger, B. R., Valadez, C., Chook, Y. M., Chung, S. S., & Liszczak, G. (2025) · Science Advances · doi:10.1126/sciadv.adu4058 · Cited by 4
“Consistently, loss- of-function somatic ETV6 missense mutations are recurrently observed in myelodysplastic syndromes (MDS) and leukemia sequencing analyses ( 5 , 6 , 11 , 12 ).”
Caballero, J. C., Sánchez‐Barba, M., Hernández-Sánchez, J. M., Such, E., Janusz, K., Sanz, G. F., Cabrero, M., Chillón, C., Cervera, J., Hurtado, A. M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03751-6 · Cited by 3
Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms
Makishima, H. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101189 · Cited by 3
Section II: Hematolymphoid malignancies
Zhang, L., Rossi, M. R., & Fisher, K. E. (2014) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2014.08.005 · Cited by 3
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
Shadman, M. S., & Deeg, J. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.056 · Cited by 4
Miller, K. B., & Pilichowska, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_23 · Cited by 4
Huang, J., Wang, M., Zhang, Z., & Chen, S. (2025) · Hematology · doi:10.1080/16078454.2025.2594370 · Cited by 2
“This progression follows a canonical trajectory, initiating with early mutations in epigenetic regulators (e.g. TET2 , DNMT3A ) and spliceosome components (e.g. SF3B1 , SRSF2 , U2AF1 ), which are typically present at high variant allele frequencies (VAF) at diagnosis [32–34].”
Chung, C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211036154 · Cited by 2
Rise of the Clones: Myelodysplastic Syndrome to Secondary Acute Myeloid Leukemia
Romine, K. A., & van Galen, P. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0046 · Cited by 2
Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2
Qiu, H., Zhang, C., Ma, X., & Li, Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8887 · Cited by 2
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
McMahon, C. M., Raddi, M. G., Mohan, S. R., & Santini, V. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473654 · Cited by 2
Novel therapeutic strategies in myelodysplastic syndromes
Chung, S. S. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000211 · Cited by 2
Development of Epigenetic Targeted Therapies in Hematological Malignancies
Prébet, T., & Gore, S. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00008-2 · Cited by 2
Savage, S. A., Pulsipher, M. A., Romano, A., & Berlyne, D. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.04.013 · Cited by 2
Cutler, J. A., Pugsley, H. R., Bennington, R. K., Fritschle, W. K., Hartmann, L., Zaidi, N., Menssen, A. J., Singleton, T. P., Xu, D., Loken, M. R., et al. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22036 · Cited by 2
“…sequencing, which has shown that genetically related founding and subclones exist in MDS and AML patients (Chen et al., 2019; Ding et al., 2012; Kim et al., 2017; Klco et al., 2014; Makishima et al., 2017; Walter et al., 2012; Walter et al., 2013; Welch et al., 2012; Xu et al., 2014).”
BackgroundCogle, C. R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju025 · Cited by 2
Borate, U. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm114.pub2 · Cited by 2
Pyka, J., Metzdorf, J., Reicherts, C., Marx, J., Leimkühler, N. B., Schneider, A., Kaivers, J., Mohring, A., Reinhardt, H. C., Stelljes, M., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.10.011 · Cited by 1
Fu, C., Chen, Z., Liu, D., Zhang, J., Pan, J., & Liang, J. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1700-1 · Cited by 1
“Our preliminary data can only provide primary clues to outline the distribution profile of the FISH-detectable abnormal clones; the recent discovery of recurrent mutations of dozen of genes in MDS cells detected by whole-genome/exome sequencing will promote the study on a more precise clonal distribution and clonal ar…”
BackgroundMiller, K. B., & Rozenvald, I. B. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_25 · Cited by 1
Beau‐Faller, M., Renaud, S., Weingertner, N., Lindner, V., Emprou, C., Quyen, P. L. V., Legrain, M., Voegeli, A., Chenard, M., Pencreach, E., et al. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30031-3 · Cited by 1
Zhao, P., Qin, J., Liu, W., Quan, R., Xiao, H., Liu, C., Li, L., Lv, Y., Zhu, Q.-Z., Wang, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10853 · Cited by 1
“The completion of whole-genome sequencing and targeted gene sequencing in patients with MDS has preliminarily revealed the molecular mechanism underlying the pathogenesis of MDS (12,13).”
Cheng, J. X., & Vardiman, J. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-32189-5_24 · Cited by 1
Wang, L., Chen, S., Shen, Y., & Si, P. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.993952 · Cited by 1
Nann, D., Rau, A., Mahmutovic, L., Steinhilber, J., Meca, V., Federmann, B., Vogel, W., Bonzheim, I., Quintanilla‐Martínez, L., & Fend, F. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03627-1 · Cited by 1
Clonal hematopoiesis in telomere biology disorders
Sande, C. M., & Babushok, D. V. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.02.004 · Cited by 1
Downregulated stromal antigen 2 expression in de novo acute myeloid leukemia patients
Han, Q., He, X., Wu, L., Gao, F., Ye, J., Wu, L., Chen, L., Jiang, X., Sun, M., & Chen, S. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4030 · Cited by 1
“Mutations in the cohesin complex including STAG2 have recently been reported in a number of AML and myelodysplastic syndrome cases (15-20).”
Clinical Prospects of Myelodysplastic Syndromes
Harada, H. (2015) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.11.187 · Cited by 1
Mazzarella, L. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.390 · Cited by 1
Enigmatic missense mutations can cause disease via creation of de novo nuclear export signalsPreprint
McConville, B. M., Thomas, T., Beckner, R. L., Valadez, C., Chook, Y. M., Chung, S. S., & Liszczak, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.24.590854 · Cited by 1
“Consistently, loss-of-function somatic ETV6 missense mutations are recurrently observed in MDS and leukemia sequencing analyses 8,9,14,15 .”
BackgroundU2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAsPreprint
Garcia, G. R., Palangat, M., Moraly, J., Donovan, B. T., Wang, B., Phadke, I., Sturgill, D. M., Chen, J., Short, B., Rivero, G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613780 · Cited by 1
“13 21-23 Notably, mitochondrial dysfunction is a defining phenotype of MDS 19 , and splicing factor mutations are a defining genotype: >50% of MDS patients harbor mutations in U2AF1, SRSF2, ZRSR2, or SF3B1 within their hematopoietic stem and progenitor cells (HSPCs).”
BackgroundClinical and molecular effects of azacitidine in the myelodysplastic syndromes
Tobiasson, M. (2015) · Figshare
Genomics of inherited bone marrow failure and myelodysplasia
Zhang, M. Y. (2015) · ResearchWorks at the University of Washington (University of Washington)
Role of Hypomethylating Agents in the Treatment of Bone Marrow Failure
Ebert, B. L. (2015)
Case Study: Treatment Decisions in Secondary AML
Altman, J. K. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.058
Global analysis of alternative splicing in human cells of myeloid origin
Alberto, L. P. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/74234
“In addition, clonal cells can also acquire subclonal driver mutations, such as in genes involved in chromatin modification or regulation of transcription (Walter et al. 2013).”
BackgroundClonal Hematopoiesis and Cytopenias in the Elderly
Guy, D. G., Afzal, A., & Jacoby, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96487-4_12
Pharmacogenomics: Success and Challenges
Hussaini, M., & McLeod, H. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_38
[New understanding on the pathogenic mechanism of myelodysplastic syndromes in adults and children].
Chen, Z. X. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.09.018
[Clinical analysis of VAF value difference of gene mutation in myelodysplastic syndrome].
Lyu, X., Li, Y., Guo, Z., Hu, J., Fan, R., & Song, Y. P. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.10.016
The Origin of Therapy-Related AML Lies Deep Within
Becker, P. S. (2015) · The Hematologist · doi:10.1182/hem.v12.2.3699
Keel, S. (2017) · The Hematologist · doi:10.1182/hem.v14.2.7096
Choi, J. K., Klco, J. M., & Mirza, K. (2018) · Molecular pathology library · doi:10.1007/978-3-319-89626-7_6
Blau, O., Schwarzer, R., & Blau, I. W. (2016) · EMJ Oncology · doi:10.33590/emjoncol/10311896
Leukemia initiating cells and their niche
Rahnemoon, A. R. (2023) · Cancer Research and Cellular Therapeutics · doi:10.31579/2640-1053/166
Jacoby, M. A., Duncavage, E., Khanna, A., Chang, G. S., Srivatsan, S. N., Miller, C. A., Gao, F., Robinson, J., Shao, J., Fulton, R. S., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02426-0
“We also observed that the median VAF of subclones in the bone marrow and blood correlated well ( R 2 = 0.66, p 0.0001), although subclone VAFs tended to be lower in the peripheral blood than in the bone marrow (Supplementary Fig.”
InfluentialSelf-citationLaaref, A. M. (2017) · theses.fr (ABES) · doi:10.70675/c2cfd784z5dd2z47cez9ddcz4ee6e8af424e
Les thrombopénies héréditaires rares : implications des gènes ETV6, ITGA2B, ITGB3
Favier, M. (2017) · theses.fr (ABES) · doi:10.70675/f85e6d34z2301z4deez9be8z4964be9fdf24
Martignoles, J. (2022) · theses.fr (ABES) · doi:10.70675/dc56799dzc2f9z460fz892az3a689bd2251a
Metadata
- Authors
- Walter, M. J., Shen, D., Shao, J., Ding, L., White, B. S., Kandoth, C., Miller, C. A., Niu, B., McLellan, M. D., Dees, N. D., Fulton, R., Elliot, K., Heath, S., Grillot, M., Westervelt, P., Link, D. C., DiPersio, J. F., Mardis, E., Ley, T. J., Wilson, R. K., & Graubert, T. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Graubert, T A
- ORCID
- Venue
- Leukemia
- Published
- 2013-02-27
- Volume
- 27
- Issue
- 6
- Pages
- 1275-1282
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3736571
- OpenAlex
- W2041596445
- Cited by
- 284
- References
- 31
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 20 · 2021: 15 · 2020: 16 · 2019: 15 · 2018: 29 · 2017: 36 · 2016: 32 · 2015: 34 · 2014: 37 · 2013: 23
- FWCI
- 30.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (RC2HL102927, R01HL082973)
- National Human Genome Research Institute (U01HG006517, U54HG003079)
- National Cancer Institute (P01CA101937, P30CA091842)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- myelodysplastic syndrome, clonal heterogeneity, subclones, variant allele frequency, secondary acute myeloid leukemia, clonal architecture, chromosomal abnormalities
- MeSH terms
- Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
